ATyr Pharma Announces Publication Demonstrating Efficacy Of Efzofitimod In Pulmonary Sarcoidosis In The European Respiratory Journal
ATyr Pharma Announces Publication Demonstrating Efficacy Of Efzofitimod In Pulmonary Sarcoidosis In The European Respiratory Journal
Post hoc analysis of Phase 1b/2a study demonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs subtherapeutic (1.0 mg/kg efzofitimod and placebo) groups.
对1b/2a期研究的事后分析表明，治疗组（3.0和5.0 mg/kg efzofitimod）与非治疗组（1.0 mg/kg efzofitimod 和安慰剂）组中皮质类固醇的首次复发时间存在统计学上的显著差异。
54.4% of patients in the subtherapeutic group relapsed following corticosteroid taper, compared to 7.7% in the therapeutic group.
亚治疗组中有54.4％的患者在皮质类固醇逐渐减少后复发，而治疗组的这一比例为7.7％。
SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication of a post hoc analysis of the Phase 1b/2a clinical trial of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease, in the European Respiratory Journal. The publication, entitled, "Therapeutic Doses of Efzofitimod Demonstrate Efficacy in Pulmonary Sarcoidosis," is available on the Journal's website and at: .
圣地亚哥，2024年10月2日（GLOBE NEWSWIRE）——从事利用其专有tRNA合成酶平台发现和开发同类首创药物的临床阶段生物技术公司Atyr Pharma, Inc.（纳斯达克股票代码：ATYR）（“aTYR” 或 “公司”）今天宣布发布对其主要候选治疗药物efzofitimod的1b/2a期临床试验的后期分析，《欧洲呼吸杂志》载于肺结节病（一种主要的间质性肺病）患者。该出版物名为 “Efzofitimod的治疗剂量显示出对肺结节病的疗效”，可在该期刊的网站上查阅，网址为：。
